{"id":"W2892110441","doi":"10.1200/jco.2016.34.15_suppl.8010","title":"Pembrolizumab in combination with lenalidomide and low-dose dexamethasone for relapsed/refractory multiple myeloma (RRMM): Final efficacy and safety analysis.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lenalidomide; Neutropenia; Pembrolizumab; Multiple myeloma; Internal medicine; Tolerability; Dexamethasone; Population; Refractory (planetary science); Adverse effect; Oncology; Toxicity; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001966706,0.0007229752,0.001114131,0.0005715907,0.0003510704,0.0007423571,0.0007050313,0.0007656508,0.002342412],"category_scores_gemma":[0.0008091778,0.0003830807,0.001220842,0.0004174437,0.0003760452,0.0004319829,0.0002644697,0.001547166,0.0006099886],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001240995,"about_ca_system_score_gemma":0.0009909341,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007382333,"about_ca_topic_score_gemma":0.002884967,"domain_scores_codex":[0.9993693,0.0002932447,0.00004359222,0.00008278032,0.0001126405,0.00009851635],"domain_scores_gemma":[0.9994061,0.0001066124,0.0001888389,0.00007071644,0.00005002973,0.0001777143],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4519079,0.04555274,0.03444608,0.001429588,0.004754487,0.001292485,0.0004135538,0.003963403,0.09884972,0.0005034627,0.006999099,0.3498874],"study_design_scores_gemma":[0.2369935,0.610201,0.1112567,0.0001870021,0.003273523,0.002405167,0.0001080721,0.00335895,0.01781611,0.0003373591,0.01400581,0.00005676854],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9903243,0.004028502,0.0006504197,0.0003871598,0.00003858892,0.001472218,0.001115454,0.00007724945,0.001906083],"genre_scores_gemma":[0.9935389,0.001260352,0.001108896,0.0004555446,0.00006443757,0.0005443185,0.00193872,0.00001931318,0.001069544],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002342412,"threshold_uncertainty_score":0.01040101,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1014510700085155,"score_gpt":0.4374980002694009,"score_spread":0.3360469302608854,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}